Cell therapy (NK cells) · Kills target cells · developed by Fate Therapeutics
FT538 is an allogeneic natural killer (NK) cell therapy derived from a clonal induced pluripotent stem cell line and engineered to express a high-affinity non-cleavable CD16 Fc receptor and an IL-15/IL-15 receptor alpha fusion, with CD38 expression eliminated. It binds stress-induced ligands on tumor cells and, with monoclonal antibodies, mediates antibody-dependent cellular cytotoxicity. It is studied in adult patients with solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05069935 | Phase 1 | Solid Tumor, Adult | Terminated | FATE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Solid Tumor, Adult
Updated Nov 15, 2026. Something wrong or missing? Report it on the FATE page.
See FATE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
FATE catalysts and pipeline →